The Southern African pharmaceutical industry
The Southern African pharmaceutical industry plays a critical role in the healthcare and economy of the region- driven by South Africa. It is however faced with notable supply chain challenges but there are some opportunities for growth and improvement.
The pharmaceutical market in South Africa, the region's largest contributor, was valued at approximately USD 3.61 billion in 2024. Over 70% of the medicines in South Africa are imported, primarily from India, China, and Europe. Africa's pharmaceutical industry is projected to grow at a CAGR of 6%–8%, reaching $70 billion by 2030. Growth is driven by increasing population, urbanisation, and demand for better healthcare services.
Heavy reliance on imported active pharmaceutical ingredients (APIs) (over 70% in South Africa) and finished products makes the supply chain vulnerable to global disruptions, as seen during the COVID-19 pandemic. Inadequate port, transport, and cold chain storage infrastructure lead to delays and compromised product quality. Fragmented regulations across Southern African countries result in inefficiencies, such as delayed approvals for imports or new products. Developing local pharmaceutical industries requires substantial investment, with estimates suggesting that $111 billion will be needed by 2030 to fund growth and infrastructure development.
Rising transportation and logistical costs due to fuel price volatility and inefficiencies increase medicine prices for end-users. Weak tracking mechanisms contribute to the prevalence of counterfeit drugs in the supply chain, undermining public health and trust.
The pharmaceutical market in South Africa, the region's largest contributor, was valued at approximately USD 3.61 billion in 2024. Over 70% of the medicines in South Africa are imported, primarily from India, China, and Europe. Africa's pharmaceutical industry is projected to grow at a CAGR of 6%–8%, reaching $70 billion by 2030. Growth is driven by increasing population, urbanisation, and demand for better healthcare services.
Heavy reliance on imported active pharmaceutical ingredients (APIs) (over 70% in South Africa) and finished products makes the supply chain vulnerable to global disruptions, as seen during the COVID-19 pandemic. Inadequate port, transport, and cold chain storage infrastructure lead to delays and compromised product quality. Fragmented regulations across Southern African countries result in inefficiencies, such as delayed approvals for imports or new products. Developing local pharmaceutical industries requires substantial investment, with estimates suggesting that $111 billion will be needed by 2030 to fund growth and infrastructure development.
Rising transportation and logistical costs due to fuel price volatility and inefficiencies increase medicine prices for end-users. Weak tracking mechanisms contribute to the prevalence of counterfeit drugs in the supply chain, undermining public health and trust.
Possible Solution
Incentivise the local production of APIs and finished pharmaceuticals to reduce dependency on imports. Encouraging local production of medicines can reduce dependency on imports, enhance supply chain resilience, and stimulate economic growth. South Africa’s Department of Trade, Industry, and Competition has launched initiatives to promote local production through tax incentives. Investing in cold chain storage, modernising the transport systems, and improving port efficiencies to facilitate faster and safer distribution.
Streamlining regulatory processes and aligning them with international standards can facilitate quicker access to new medicines and attract foreign investment. Allocating resources to R&D can foster innovation, leading to the development of new treatments tailored to regional health challenges. Regional collaborations under the African Continental Free Trade Agreement (AfCFTA) aim to improve infrastructure across borders.
Implement digital tracking systems to enhance transparency, combat counterfeiting, and improve inventory management. Pilot programs in Kenya and South Africa are using blockchain for supply chain tracking.
Standardise regulations across the Southern African Development Community (SADC) to streamline approvals and reduce administrative bottlenecks. The African Medicines Agency (AMA) is working on harmonising pharmaceutical regulations continent-wide.
Collaborate between governments and private entities to fund infrastructure, technology adoption, and workforce training. PPPs have been effective in creating regional distribution hubs, such as those for vaccines. Foster research into regional diseases and train a skilled workforce to manage and optimise pharmaceutical supply chains. Universities and private companies are forming alliances to develop expertise in pharmaceutical logistics.
Streamlining regulatory processes and aligning them with international standards can facilitate quicker access to new medicines and attract foreign investment. Allocating resources to R&D can foster innovation, leading to the development of new treatments tailored to regional health challenges. Regional collaborations under the African Continental Free Trade Agreement (AfCFTA) aim to improve infrastructure across borders.
Implement digital tracking systems to enhance transparency, combat counterfeiting, and improve inventory management. Pilot programs in Kenya and South Africa are using blockchain for supply chain tracking.
Standardise regulations across the Southern African Development Community (SADC) to streamline approvals and reduce administrative bottlenecks. The African Medicines Agency (AMA) is working on harmonising pharmaceutical regulations continent-wide.
Collaborate between governments and private entities to fund infrastructure, technology adoption, and workforce training. PPPs have been effective in creating regional distribution hubs, such as those for vaccines. Foster research into regional diseases and train a skilled workforce to manage and optimise pharmaceutical supply chains. Universities and private companies are forming alliances to develop expertise in pharmaceutical logistics.
Key Benefits of Resolving Supply Chain Issues
• Enhanced access to affordable medicines for underserved populations.
• Reduction in costs and lead times, improving profitability for local producers.
• Greater resilience to global disruptions, ensuring a stable supply of essential medicines.
• Strengthened regional collaboration under frameworks like AfCFTA, boosting trade and economic growth.
By addressing these supply chain challenges and implementing robust solutions, the Southern African pharmaceutical industry can achieve sustainable growth while improving healthcare outcomes for millions.
Mahumoscm.co.za @mahumoscm @mahumops AfCFTA #supplychain #supplychainmanagement #distribution @thedtic #coldchain #pharmaceutical @AMA @SADC #API #SADC @DTI #AfCFTA #transport #logistics Bayer | Pharmaceuticals Aspen Pharma Group @norvatis Cipla Pfizer Sanofi Roche Africa Abbott GSK Kenvue
• Reduction in costs and lead times, improving profitability for local producers.
• Greater resilience to global disruptions, ensuring a stable supply of essential medicines.
• Strengthened regional collaboration under frameworks like AfCFTA, boosting trade and economic growth.
By addressing these supply chain challenges and implementing robust solutions, the Southern African pharmaceutical industry can achieve sustainable growth while improving healthcare outcomes for millions.
Mahumoscm.co.za @mahumoscm @mahumops AfCFTA #supplychain #supplychainmanagement #distribution @thedtic #coldchain #pharmaceutical @AMA @SADC #API #SADC @DTI #AfCFTA #transport #logistics Bayer | Pharmaceuticals Aspen Pharma Group @norvatis Cipla Pfizer Sanofi Roche Africa Abbott GSK Kenvue
